Novo Nordisk to acquire obesity drug developer Inversago
Danish drug maker Novo Nordisk said on Thursday it would acquire Canadian company Inversago Pharma in a $1.07 billion deal including the development of an appetite regulator.
Novo Nordisk, now Europe's second-largest company by market cap, lifts outlook after 46% profit rise
Novo Nordisk, the Danish drugmaker that's now the second-largest company in Europe by market capitalization, on Thursday reported a 46% rise in profit and lifted its outlook for the year.
Wegovy-maker Novo Nordisk sales soar 30% on strong demand for its weight-loss drug
The Danish company's diabetes and obesity division performed particularly well, bolstered by interest in its blockbuster injections Wegovy and Ozempic.
Novo Nordisk hikes FY outlook as demand for weight-loss drug Wegovy soars
Danish drugmaker Novo Nordisk on Thursday hiked its full-year profit and sales forecast for a second time as its weight-loss and diabetes drugs flew off the shelves in the United States.
Novo Nordisk Soars To New High On Weight-Loss Drug Trial Results
Weight-loss drugs are the pharmaceutical industry's equivalent of AI, in the sense of being a product with the capability to send shares soaring. Novo Nordisk A/S NYSE: NVO, maker of Wegovy, saw it...
Weight loss injections 'can lower heart attack and stroke risk by a fifth'
Weight loss injections can lower the risk of a heart attack or stroke in obese people with cardiovascular disease by a fifth, a new study has suggested.
Novo Nordisk weight loss drug Wegovy cuts heart disease risk by 20%, trial shows
Novo Nordisk said the results of a late-stage drug trial showed weight loss drug Wegovy also can cut the risk of heart disease in certain patients.
Novo Nordisk ADRs Surge After Wegovy Shown to Reduce Heart Attack, Stroke Risks
ADRs of Novo Nordisk surged to an all-time high after a study found Novo Nordisk's Wegovy weight-loss drug also helped cut risk of major adverse cardiovascular events by 20%.
Novo weight-loss drug Wegovy shows heart benefit in trial
The trial showed that patients on Wegovy had a 20% lower incidence of heart attack, stroke or death from heart disease compared to those on a placebo, Novo said.
The Obesity Drug Revolution Just Got Real
New data show Novo Nordisk's Wegovy reduces risk of heart attack and stroke, paving the way for greater insurance coverage.
Novo Nordisk shares pop after key trial data shows Wegovy cuts risk of heart attack or stroke by 20%
Jared Holz, Mizuho healthcare sector strategist, joins 'Squawk Box' to discuss the impact of Novo Nordisk's weight-loss drug Wegovy cuts risk of heart attack or stroke by 20%, the obesity drug mark...
Novo Nordisk weight loss drug impresses in heart trial
Novo Nordisk (NYSE:NVO) shares soared as the Danish pharma reported its new treatment Wegovy reduced heart problems well as weight in on ongoing trial. Obesity treatment semaglutide (marketed as We...
Novo Nordisk shares pop after key trial data shows Wegovy cuts risk of heart attack or stroke by 20%
The results of the trial were seen as a major boost for the firm's hopes of moving beyond Wegovy's image as a "vanity drug."
Novo Nordisk says Wegovy reduced risk of adverse cardiovascular events by 20% in adults with obesity in trial
Novo Nordisk's U.S.-listed stock NVO, +3.04% NOVO.B, +10.32% rose 10% premarket Tuesday, after the company said its obesity treatment semaglutide, marketed as Wegovy, met its main goal in a trial e...
Related Companies